 HAYWARD, Calif.--BUSINESS WIRE--Arcus Biosciences, Inc. NYSE:RCUS, an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today reported financial results for the fourth quarter and year ended December 31, 2020 and provided operational highlights. With 735 million in cash at the end of the year, plus 220 million from Gileads recent equity investment, we are extremely well-positioned to accelerate the advancement of our pipeline, initiate our firs 